Evidence map›Paper›PMID 37982638›Full record

ArticlePharmaceutical patent analyst2023

Steroid sulfatase inhibitors and sulfated C19 steroids for proteotoxicity-related diseases: a patent spotlight.

Rami A Al-Horani

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutical patent analyst, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Rami A Al-HoraniDivision of Basic Pharmaceutical Sciences, College of Pharmacy, Xavier University of Louisiana, New Orleans, LA 70125, USA.ORCID 0000-0001-9146-2662
Xavier University of Louisiana · US

Funding

Inhibitors of Human Factor XIIIa as New AnticoagulantsR16GM149412 · NIGMS · XAVIER UNIVERSITY OF LOUISIANA · PI Rami A Al-Horani · 2023 to 2026
$599k
Inhibitors of the Intrinsic Pathway of Coagulation as New AnticoagulantsSC3GM131986 · NIGMS · XAVIER UNIVERSITY OF LOUISIANA · PI AL-HORANI, RAMI A · 2019 to 2022
$426k
NIGMS NIH HHS R16 GM149412NIGMS NIH HHS SC3 GM131986NIGMS NIH HHS SC3GM131986
6 · The paper itself

Abstract

Aging and proteotoxicity go hand in hand. Inhibiting proteotoxicity has been proposed to extend lifespan. This invention describes a new strategy to limit proteotoxicity and to extend the lifespan. Loss of function of

Indexed as

Steryl-SulfataseSulfatesAgingAnimalsCaenorhabditis elegansProtein AggregatesSteroidsProtein AggregatesSteroidsSteryl-SulfataseSulfatesaggregation-related diseasesagingAlzheimer's diseasedehydroepiandrosteroneHuntington's diseaselongevityParkinson's diseaseproteotoxicitysteroid sulfatase inhibitorsteroid sulfate

Identifiers

PMID37982638
PMCPMC10782412
OpenAlexW4388827059

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.